Journal Home > Volume 12 , Issue 5
Food Science and Human Wellness 2023, 12(5): 1660-1673 https://doi.org/10.1016/j.fshw.2023.02.023
Research Article | Open Access | Issue | Published: 21 March 2023

Alleviating effects and mechanisms of action of large-leaf yellow tea drinking on diabetes and diabetic nephropathy in mice

Show Author's Information Guangshan Zhaoa,b,1,  Jianyuan Tengb,1,  Ruixia Dongc,d,1,  Qiuyan Bane,  Lian Yangf,  Kang Duf,  Yifei Wangb,  Hanlin Pub( ),  Chung S. Yangg,h( ),  Zhe Renb( )
Innovation Team of Food Nutrition and Safety Control, College of Food Science & Technology, Henan Agricultural University, Zhengzhou 450002, China
Biology Postdoctoral Research Station, Department of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
College of Horticulture, Jinling Institute of Technology, Nanjing 211169, China
Department of Forestry and Technology, Lishui Vocational and Technical College, Lishui 323000, China
Department of Tea Science, College of Horticulture, Henan Agricultural University, Zhengzhou 450002, China
Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway 08901, USA
International Joint Research Laboratory of Tea Chemistry and Health Effects, Anhui Agricultural University, Hefei 230036, China

1 These authors contributed equally to this work.

Peer review under responsibility of KeAi Communications Co., Ltd.

Keywords:
Gut microbiota, Diabetes, Diabetic nephropathy, Glucose and lipid metabolism, Large-leaf yellow tea
Cite this article:
Zhao G, Teng J, Dong R, et al. Alleviating effects and mechanisms of action of large-leaf yellow tea drinking on diabetes and diabetic nephropathy in mice. Food Science and Human Wellness, 2023, 12(5): 1660-1673. https://doi.org/10.1016/j.fshw.2023.02.023
Download citation
EndNote(RIS)
BibTeX

420

Views

18

Downloads

Citations

8

Crossref

6

WoS

7

Scopus

0

CSCD

Abstract Full text About this article

Our previous study found that large-leaf yellow tea (LYT) had interesting hypoglycemic activity in high-fat diet-induced obese mice and highly safety in healthy mice. To study the anti-diabetic potential of LYT, the present study further investigated the preventive effects and mechanisms of action of LYT administration on diabetes and diabetic nephropathy in high-fat diet plus streptozotocin-induced diabetic mice. Results showed that LYT infusions (1/100 and 1/50, m/V) as drinking fluid for 4 weeks reduced diabetic polydipsia and polyuria, enhanced glucose tolerance and insulin sensitivity, and lowered fasting blood glucose level. The underlying mechanisms involve downregulation of gluconeogenesis (lower protein levels of TXNIP and FBP and enzyme activity of FBP), upregulation of lipid catabolism (higher protein levels of CPT-1α and PPARα), downregulation of lipogenesis (lower protein level of SREBP-1), and modification of the structure and abundance of gut microbiota to modulate metabolic homeostasis. Moreover, LYT administration prevented diabetic nephropathy, possibly due to reduced glucose-caused osmotic diuresis and lowered levels of renal PKC-β2, NLRP3 as well as membrane PKC-α, AQP2 and glycosylated AQP2 proteins. Taken together, LYT exhibits the activities in alleviating diabetic symptoms, ameliorating glucose and lipid dysmetabolism and fatty liver, and preventing diabetic nephropathy in diabetic mice. These activities may be explored for the prevention and treatment of diabetes in humans.


menu
Abstract
Full text
Outline
About this article

Alleviating effects and mechanisms of action of large-leaf yellow tea drinking on diabetes and diabetic nephropathy in mice

Show Author's information Guangshan Zhaoa,b,1, Jianyuan Tengb,1, Ruixia Dongc,d,1, Qiuyan Bane, Lian Yangf, Kang Duf, Yifei Wangb, Hanlin Pub( ), Chung S. Yangg,h( ), Zhe Renb( )
Innovation Team of Food Nutrition and Safety Control, College of Food Science & Technology, Henan Agricultural University, Zhengzhou 450002, China
Biology Postdoctoral Research Station, Department of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
College of Horticulture, Jinling Institute of Technology, Nanjing 211169, China
Department of Forestry and Technology, Lishui Vocational and Technical College, Lishui 323000, China
Department of Tea Science, College of Horticulture, Henan Agricultural University, Zhengzhou 450002, China
Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway 08901, USA
International Joint Research Laboratory of Tea Chemistry and Health Effects, Anhui Agricultural University, Hefei 230036, China

1 These authors contributed equally to this work.

Peer review under responsibility of KeAi Communications Co., Ltd.

Abstract

Our previous study found that large-leaf yellow tea (LYT) had interesting hypoglycemic activity in high-fat diet-induced obese mice and highly safety in healthy mice. To study the anti-diabetic potential of LYT, the present study further investigated the preventive effects and mechanisms of action of LYT administration on diabetes and diabetic nephropathy in high-fat diet plus streptozotocin-induced diabetic mice. Results showed that LYT infusions (1/100 and 1/50, m/V) as drinking fluid for 4 weeks reduced diabetic polydipsia and polyuria, enhanced glucose tolerance and insulin sensitivity, and lowered fasting blood glucose level. The underlying mechanisms involve downregulation of gluconeogenesis (lower protein levels of TXNIP and FBP and enzyme activity of FBP), upregulation of lipid catabolism (higher protein levels of CPT-1α and PPARα), downregulation of lipogenesis (lower protein level of SREBP-1), and modification of the structure and abundance of gut microbiota to modulate metabolic homeostasis. Moreover, LYT administration prevented diabetic nephropathy, possibly due to reduced glucose-caused osmotic diuresis and lowered levels of renal PKC-β2, NLRP3 as well as membrane PKC-α, AQP2 and glycosylated AQP2 proteins. Taken together, LYT exhibits the activities in alleviating diabetic symptoms, ameliorating glucose and lipid dysmetabolism and fatty liver, and preventing diabetic nephropathy in diabetic mice. These activities may be explored for the prevention and treatment of diabetes in humans.

Keywords: Gut microbiota, Diabetes, Diabetic nephropathy, Glucose and lipid metabolism, Large-leaf yellow tea

References(74)

[1]

K.G. Alberti, J. Shaw, Global and societal implications of the diabetes epidemic, Nature 414 (2001) 782-787. https://doi.org/10.1038/414782a.
DOI Google Scholar
[2]

M. Stumvoll, C. Meyer, A. Mitrakou, et al., Renal glucose production and utilization: new aspects in humans, Diabetologia 40 (1997) 749-757. https://doi.org/10.1007/s001250050745.
DOI Google Scholar
[3]

J.E. Gerich, C. Meyer, H.J. Woerle, et al., Renal gluconeogenesis: its importance in human glucose homeostasis, Diabetes Care 24 (2001) 382-391. https://doi.org/10.2337/diacare.24.2.382.
DOI Google Scholar
[4]

A. Mitrakou, Kidney: its impact on glucose homeostasis and hormonal regulation, Diabetes Res. Clin. Pract. 93 (2011) S66-S72. https://doi.org/10.1016/S0168-8227(11)70016-X.
DOI Google Scholar
[5]

G. Lemieux, M.R. Aranda, P. Fournel, et al., Renal enzymes during experimental diabetes mellitus in the rat. Role of insulin, carbohydrate metabolism, and ketoacidosis, Can. J. Physiol. Pharmacol. 62 (1984) 70-75. https://doi.org/10.1139/y84-010.
DOI Google Scholar
[6]

G. Mithieux, H. Vidal, C. Zitoun, et al., Glucose-6-phosphatase mRNA and activity are increased to the same extent in kidney and liver of diabetic rats, Diabetes 45 (1996) 891-896. https://doi.org/10.2337/diab.45.7.891.
DOI Google Scholar
[7]

G. Weber, M.A. Lea, H.J. Convery, et al., Regulation of gluconeogenesis and glycolysis: studies of mechanisms controlling enzyme activity, Adv. Enzyme Regul. 5 (1967) 257-300. https://doi.org/10.1016/0065-2571(67)90020-9.
DOI Google Scholar
[8]

O. Marsenic, Glucose control by the kidney: an emerging target in diabetes, Am. J. Kidney Dis. 53 (2009) 875-883. https://doi.org/10.1053/j.ajkd.2008.12.031.
DOI Google Scholar
[9]

E.C. Chao, R.R. Henry, SGLT2 inhibition-a novel strategy for diabetes treatment, Nat. Rev. Drug Discov. 9 (2010) 551-559. https://doi.org/10.1038/nrd3180.
DOI Google Scholar
[10]

E.C. Chao, A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors, Discov. Med. 11 (2011) 255-263. https://doi.org/10.3109/14653249.2010.518610.
DOI Google Scholar
[11]

A. Koh, F.D. Vadder, P. Kovatcheva-Datchary, et al., From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites, Cell 165 (2016) 1332-1345. https://doi.org/10.1016/j.cell.2016.05.041.
DOI Google Scholar
[12]

W.L. Lau, J. Savoj, M.B. Nakata, et al., Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins, Clin. Sci. (Lond). 132 (2018) 509-522. https://doi.org/10.1042/CS20171107.
DOI Google Scholar
[13]

H. Herrema, J.H. Niess, Intestinal microbial metabolites in human metabolism and type 2 diabetes, Diabetologia 63 (2020) 533-2547. https://doi.org/10.1007/s00125-020-05268-4.
DOI Google Scholar
[14]

G. Besten, K. Lange, R. Havinga, et al., Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids, Am. J. Physiol. Gastrointest. Liver Physiol. 305 (2013) G900-G910. https://doi.org/10.1152/ajpgi.00265.2013.
DOI Google Scholar
[15]

C.M. Beek, E.E. Canfora, K. Lenaerts, et al., Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men, Clin. Sci. (Lond). 130 (2016) 2073-2082. https://doi.org/10.1042/CS20160263.
DOI Google Scholar
[16]

G. Tolhurst, H. Heffron, Y.S. Lam, et al., Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2, Diabetes 61 (2012) 364-371. https://doi.org/10.2337/db11-1019.
DOI Google Scholar
[17]

E.S. Chambers, A. Viardot, A. Psichas, et al., Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults, Gut 64 (2015) 1744-1754. https://doi.org/10.1136/gutjnl-2014-307913.
DOI Google Scholar
[18]

C. Tang, K. Ahmed, A. Gille, et al., Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes, Nat. Med. 21 (2015) 173-177. https://doi.org/10.1038/nm.3779.
DOI Google Scholar
[19]

K.J. Prentice, M.B. Wheeler, FFAR out new targets for diabetes, Cell Metab. 21 (2015) 353-354. https://doi.org/10.1016/j.cmet.2015.02.015.
DOI Google Scholar
[20]

R.A. DeFronzo, Pharmacologic therapy for type 2 diabetes mellitus, Ann. Intern. Med. 131 (1999) 281-303. https://doi.org/10.7326/0003-4819-131-4-199908170-00008.
DOI Google Scholar
[21]

R. Klein, Hyperglycemia and microvascular and macrovascular disease in diabetes, Diabetes Care 18 (1995) 258-268. https://doi.org/10.2337/diacare.18.2.258.
DOI Google Scholar
[22]

S. Teutsch, J. Newman, P. Eggers, The problem of diabetic renal failure in the United States: an overview, Am. J. Kidney Dis. 13 (1989) 11-13. https://doi.org/10.1016/s0272-6386(89)80106-4.
DOI Google Scholar
[23]

T.L. Thai, M.A. Blount, J.D. Klein, et al., Lack of protein kinase C-α leads to impaired urine concentrating ability and decreased aquaporin-2 in angiotensin II-induced hypertension, Am. J. Physiol. Renal Physiol. 303 (2012) F37-F44. https://doi.org/10.1152/ajprenal.00098.2012.
DOI Google Scholar
[24]

L.J. Yao, D.Y. Huang, I.L. Pfaff, et al., Evidence for a role of protein kinase C-alpha in urine concentration, Am. J. Physio.l Renal Physiol. 287 (2004) F299-F304. https://doi.org/10.1152/ajprenal.00274.2003.
DOI Google Scholar
[25]

P.I. Nedvetsky, G. Tamma, S. Beulshausen, Regulation of aquaporin-2 trafficking, Handb. Exp. Pharmacol. 190 (2009) 133-157. https://doi.org/10.1007/978-3-540-79885-9_6.
DOI Google Scholar
[26]

Y. Yang, C. Shu, P.W. Li, Structural basis of protein kinase Cα regulation by the C-terminal tail, Biophys. J. 114 (2018) 1590-1603. https://doi.org/10.1016/j.bpj.2017.12.030.
DOI Google Scholar
[27]

G. Hendriks, M. Koudijs, B.W.M. Balkom, et al., Glycosylation is important for cell surface expression of the water channel aquaporin-2 but is not essential for tetramerization in the endoplasmic reticulum, J. Biol. Chem. 279 (2004) 2975-2983. https://doi.org/10.1074/jbc.M310767200.
DOI Google Scholar
[28]

H. Zhao, X. Yao, T.X. Wang, et al., PKCα regulates vasopressin-induced aquaporin-2 trafficking in mouse kidney collecting duct cells in vitro via altering microtubule assembly. Acta Pharmacol. Sin. 33 (2012) 230-236. https://doi.org/10.1038/aps.2011.160.
DOI Google Scholar
[29]

E.T.B. Olesen, M.R. Rützler, H.B. Moeller, et al., Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus, Proc. Natl. Acad. Sci. U.S.A. 108 (2011) 12949-12954. https://doi.org/10.1073/pnas.1104691108.
DOI Google Scholar
[30]

F. Ando, S. Uchida, Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus, Clin. Exp. Nephrol. 22 (2018) 501-507. https://doi.org/10.1007/s10157-018-1544-8.
DOI Google Scholar
[31]

Y. Ohshiro, R.C. Ma, Y. Yasuda, et al., Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice, Diabetes 55 (2006) 3112-3120. https://doi.org/10.2337/db06-0895.
DOI Google Scholar
[32]

J. Menne, J.K. Park, M. Boehne, et al., Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice, Diabetes 53 (2004) 2101-2109. https://doi.org/10.2337/diabetes.53.8.2101.
DOI Google Scholar
[33]

H. Noh, G.L. King, The role of protein kinase C activation in diabetic nephropathy, Kidney Int. Suppl. 106 (2007) S49-S53. https://doi.org/10.1038/sj.ki.5002386.
DOI Google Scholar
[34]

D. Koya, M.R. Jirousek, Y.W. Lin, et al., Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats, J. Clin. Invest. 100 (1997) 115-126. https://doi.org/10.1172/JCI119503.
DOI Google Scholar
[35]

K.R. Tuttle, P.W. Anderson, A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition, Am. J. Kidney Dis. 42 (2003) 456-465. https://doi.org/10.1016/s0272-6386(03)00741-8.
DOI Google Scholar
[36]

M.A. Bokuchava, N.I. Skobeleva, The biochemistry and technology of tea manufacture, Crit. Rev. Food Sci. Nutr. 12 (1980) 303-370. https://doi.org/10.1080/10408398009527280.
DOI Google Scholar
[37]

M.M. Han, G.S. Zhao, Y.J. Wang, et al., Corrigendum: Safety and anti-hyperglycemic efficacy of various tea types in mice, Sci. Rep. 6 (2016) 35699. https://doi.org/10.1038/srep35699.
DOI Google Scholar
[38]

N. Xu, J. Chu, M. Wang, et al., Large yellow tea attenuates macrophage-related chronic inflammation and metabolic syndrome in high-fat diet treated mice, J. Agric. Food Chem. 66 (2018) 3823-3832. https://doi.org/10.1021/acs.jafc.8b00138.
DOI Google Scholar
[39]

J. Zhou, L. Zhang, Q.L. Meng, et al., Roasting improves the hypoglycemic effects of a large-leaf yellow tea infusion by enhancing the levels of epimerized catechins that inhibit α-glucosidase, Food Funct. 9 (2018) 5162-5168. https://doi.org/10.1039/c8fo01429a.
DOI Google Scholar
[40]

C.S. Yang, J. Hong, Prevention of chronic diseases by tea: possible mechanisms and human relevance, Annu. Rev. Nutr. 33 (2013) 161-181. https://doi.org/10.1146/annurev-nutr-071811-150717.
DOI Google Scholar
[41]

C.S. Yang, J.S. Zhang, L. Zhang, et al., Mechanisms of body weight reduction and metabolic syndrome alleviation by tea, Mol. Nutr. Food Res. 60 (2016) 160-174. https://doi.org/10.1002/mnfr.201500428.
DOI Google Scholar
[42]

G.S. Zhao, X.M. Wu, W.P. Wang, et al., Tea drinking alleviates diabetic symptoms via upregulating renal water reabsorption proteins and downregulating renal gluconeogenic enzymes in db/db mice, Mol. Nutr. Food Res. (2020) e2000505. https://doi.org/10.1002/mnfr.202000505.
DOI Google Scholar
[43]

S. Carobbio, R.M. Hagen, C.J. Lelliott, et al., Adaptive changes of the Insig1/SREBP1/SCD1 set point help adipose tissue to cope with increased storage demands of obesity, Diabetes 62 (2013) 3697-3708. https://doi.org/10.2337/db12-1748.
DOI Google Scholar
[44]

V.D. Fourmestraux, H. Neubauer, C. Poussin, et al., Transcript profiling suggests that differential metabolic adaptation of mice to a high fat diet is associated with changes in liver to muscle lipid fluxes, J. Biol. Chem. 279 (2004) 50743-50753. https://doi.org/10.1074/jbc.M408014200.
DOI Google Scholar
[45]

B.M. Buckley, D.H. Williamson, Origins of blood acetate in the rat, Biochem. J. 166 (1977) 539-545. https://doi.org/10.1042/bj1660539.
DOI Google Scholar
[46]

E. Pouteau, P. Nguyen, O. Ballèvre, et al., Production rates and metabolism of short-chain fatty acids in the colon and whole body using stable isotopes, Proc. Nutr. Soc. 62 (2003) 87-93. https://doi.org/10.1079/PNS2003208.
DOI Google Scholar
[47]

T.M. Wolever, R.G. Josse, L.A. Leiter, et al., Time of day and glucose tolerance status affect serum short-chain fatty acid concentrations in humans, Metabolism 46 (1997) 805-811. https://doi.org/10.1016/s0026-0495(97)90127-x.
DOI Google Scholar
[49]

L.A. Stoddart, N.J. Smith, G. Milligan, et al., Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions, Pharmacol. Rev. 60 (2008) 405-417. https://doi.org/10.1124/pr.108.00802.
DOI Google Scholar
[50]

R. Hassouneh, R. Nasrallah, J. Zimpelmann, et al., PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes, Diabetologia 59 (2016) 1318-1328. https://doi.org/10.1007/s00125-016-3916-5.
DOI Google Scholar
[51]

Y.L. Jia, J.Z. He, L. Wang, et al., Dapagliflozin aggravates renal injury via promoting gluconeogenesis in db/db mice, Cell Physiol. Biochem. 45 (2018) 1747-1758. https://doi.org/10.1159/000487783.
DOI Google Scholar
[52]

I. Horie, N. Abiru, R. Hongo, et al., Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment, Diabetes Res. Clin. Pract. 135 (2018) 178-184. https://doi.org/10.1016/j.diabres.2017.11.016.
DOI Google Scholar
[53]

J.F. List, V. Woo, E. Morales, et al., Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes, Diabetes Care 32 (2009) 650-657. https://doi.org/10.2337/dc08-1863.
DOI Google Scholar
[54]

G. Ferrannini, T. Hach, S. Crowe, et al., Energy balance after sodium-glucose cotransporter 2 inhibition, Diabetes Care 38 (2015) 1730-1735. https://doi.org/10.2337/dc15-0355.
DOI Google Scholar
[55]

S.N. Wang, G.M. Mitu, R. Hirschberg, Osmotic polyuria: an overlooked mechanism in diabetic nephropathy, Nephrol. Dial. Transplant. 23 (2008) 2167-2172. https://doi.org/10.1093/ndt/gfn115.
DOI Google Scholar
[56]

S.M. Bagnasco, Protein kinase C-α comes to the rescue of aquaporin-2, Am. J. Physiol. Renal Physiol. 303 (2012) F35-F36. https://doi.org/10.1152/ajprenal.00225.2012.
DOI Google Scholar
[57]

J.K. Liwang, J.A. Ruiz, L.M. LaRocque, et al., Role of PKC and AMPK in hypertonicity-stimulated water reabsorption in rat inner medullary collecting ducts, Am. J. Physiol. Renal Physiol. 316 (2019) F253-F262. https://doi.org/10.1152/ajprenal.00491.2017.
DOI Google Scholar
[58]

H. Zhao, X. Yao, T.X. Wang, et al., PKCα regulates vasopressin-induced aquaporin-2 trafficking in mouse kidney collecting duct cells in vitro via altering microtubule assembly, Acta Pharmacol. Sin. 33 (2012) 230-236. https://doi.org/10.1038/aps.2011.160.
DOI Google Scholar
[59]

C.M. Borges, A. Papadimitriou, D.A. Duarte, et al., The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: a double-blind randomised clinical trial, Sci. Rep. 6 (2016) 28282. https://doi.org/10.1038/srep28282.
DOI Google Scholar
[60]

X.H. Yang, Y. Pan, X.L. Zhan, et al., Epigallocatechin-3-gallate attenuates renal damage by suppressing oxidative stress in diabetic db/db mice, Oxid. Med. Cell Longev. 2016 (2016) 2968462. https://doi.org/10.1155/2016/2968462.
DOI Google Scholar
[61]

S.J. Yan, L. Wang, Z. Li, et al., Inhibition of advanced glycation end product formation by Pu-erh tea ameliorates progression of experimental diabetic nephropathy, J. Agric. Food Chem. 60 (2012) 4102-4110. https://doi.org/10.1021/jf300347p.
DOI Google Scholar
[62]

T. Mohan, P. Velusamy, L.N. Chakrapani, et al., Impact of EGCG supplementation on the progression of diabetic nephropathy in rats: an insight into fibrosis and apoptosis, J. Agric. Food Chem. 65 (2017) 8028-8036. https://doi.org/10.1021/acs.jafc.7b03301.
DOI Google Scholar
[63]

W.M. Renno, S. Abdeen, M. Alkhalaf, et al., Effect of green tea on kidney tubules of diabetic rats, Br. J. Nutr. 100 (2008) 652-659. https://doi.org/10.1017/S0007114508911533.
DOI Google Scholar
[64]

N. Hwang, T. Eom, S.K. Gupta, et al., Genes and gut bacteria involved in luminal butyrate reduction caused by diet and loperamide, Genes (Basel) 8 (2017) 350. https://doi.org/10.3390/genes8120350.
DOI Google Scholar
[65]

D. Ma, A.C. Wang, I. Parikh, et al., Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice, Sci. Rep. 8 (2018) 6670. https://doi.org/10.1038/s41598-018-25190-5.
DOI Google Scholar
[66]

C. Kong, R.Y. Gao, X.B. Yan, et al., Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet, Nutrition 60 (2019) 175-184. https://doi.org/10.1016/j.nut.2018.10.002.
DOI Google Scholar
[67]

J. Yin, Y.Y. Li, H. Han, et al., Melatonin reprogramming of gut microbiota improves lipid dysmetabolism in high-fat diet-fed mice, J. Pineal Res. 65 (2018) e12524. https://doi.org/10.1111/jpi.12524.
DOI Google Scholar
[68]

W.J. Tang, X.R. Yao, F. Xia, et al., Modulation of the gut microbiota in rats by hugan qingzhi tablets during the treatment of high-fat-diet-induced nonalcoholic fatty liver disease, Oxid. Med. Cell Longev. 2018 (2018) 7261619. https://doi.org/10.1155/2018/7261619.
DOI Google Scholar
[69]

K. Wang, M.F. Liao, N. Zhou, et al., Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids, Cell Rep. 26 (2019) 222-235. https://doi.org/10.1016/j.celrep.2018.12.028.
DOI Google Scholar
[70]

Y. Jung, I. Kim, M. Mannaa, et al., Effect of kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease, Food Sci. Biotechnol. 28 (2018) 261-267. https://doi.org/10.1007/s10068-018-0433-y.
DOI Google Scholar
[71]

H. Mu, Q. Zhou, R.Y. Yang, et al., Naringin attenuates high fat diet induced non-alcoholic fatty liver disease and gut bacterial dysbiosis in mice, Front. Microbiol. 11 (2020) 585066. https://doi.org/10.3389/fmicb.2020.585066.
DOI Google Scholar
[72]

A. Schwiertz, D. Taras, K. Schäfer, et al., Microbiota and SCFA in lean and overweight healthy subjects, Obesity (Silver Spring) 18 (2010) 190-195. https://doi.org/10.1038/oby.2009.167.
DOI Google Scholar
[73]

J.W. Li, B. Fang, G.F. Pang, et al., Age- and diet-specific effects of chronic exposure to chlorpyrifos on hormones, inflammation and gut microbiota in rats, Pestic. Biochem. Physiol. 159 (2019) 68-79. https://doi.org/10.1016/j.pestbp.2019.05.018.
DOI Google Scholar
[74]

N. Salazar, E.M. Dewulf, A.M. Neyrinck, et al., Inulin-type fructans modulate intestinal bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women, Clin. Nutr. 34 (2015) 501-507. https://doi.org/10.1016/j.clnu.2014.06.001.
DOI Google Scholar
[75]

K. Bouter, G.J. Bakker, E. Levin, et al., Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects, Clin. Transl. Gastroenterol. 9 (2018) 155. https://doi.org/10.1038/s41424-018-0025-4.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 21 April 2021
Revised: 27 May 2021
Accepted: 30 May 2021
Published: 21 March 2023
Issue date: September 2023

Copyright

© 2023 Beijing Academy of Food Sciences.

Acknowledgements

Acknowledgement

This work was supported by the Open Fund of State Key Laboratory of Tea Plant Biology and Utilization (SKLTOF20200127 and SKLT0F20200108), the Open Fund of Key Laboratory of Tea Plant Resources Comprehensive Development in South Henan Province (HNKLTOF2020005) and the Zhejiang Provincial Basic Public Welfare Research Program Project (LGF20H280007).

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return